Contemporary therapy of atrial fibrillation

Xing Sheng Yang, Jing Ping Sun, Cheuk Man Yu

Division of Cardiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

DOI: 10.4236/wjcd.2012.23018                

Abstract

Atrial fibrillation (AF) is estimated that by 2010, approximately 2.6 million people will be affected in USA; by 2050, that number may increase to 10 million patients. Generally, rate control alone is reasonable in some AF patients, especially asymptomatic patients. Restoration and maintenance of sinus rhythm (SR) may be achieved by means of cardioversion, drugs or/ and catheter ablation. Pharmacological therapy can be useful to maintain SR and prevent tachycardia-induced cardiomyopathy. All patients with AF regardless of whether a rhythm or rate control strategy recommend anticoagulant, antiplatelet or both combined therapy for prevention of thromboembolism, except those with lone AF or contraindications. Drug selection should be based upon the absolute risk of stroke, bleeding, the relative risk and benefit for a given patient. Biventricular pacing may overcome many of the adverse hemodynamic effects associated with RV pacing alone. A target individual ectopic foci ablation within the pulmonary vein (PV) has evolved to circumferential electrical isolation of the entire PV musculature. Cavotricuspid isthmus should be considered as first-line therapy for patients with typical atrial flutter. Completely non-fluoroscopic ablation guided by Real-Time Magnetic Resonance Imaging (RTMRI) using a steerable and non-ferromagnetic catheter is a promising novel technology in interventional electrophysiology.

Keywords

Atrial Fibrillation; Antiarrhythmic Drug; Anticoagulant Therapy; Antiplatelet Therapy; Cardioversion; Catheter Ablation

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Naccarelli, G.V. (2007) Easing the burden and halting the progression of a persistent, yet highly treatable disorder. Research & Review in Atrial Fibillation, 1, 2.
[2]	Chen, L.Y. and Shen, W.K. (2007) Epidemiology of atrial fibrillation: A current perspective. Heart Rhythm, 4, 51- 56.
[3]	Go, A.S., Hylek, E.M., Phillips, J.A., et al. (2001) Prevalence of diagnosed AF in adults: national implications for rhythm management and stroke prevent: The Anticoagulation and Risk Fraction in AF (ATRIA) Study. Journal of the American Medical Association, 285, 2370-2375. doi:10.1001/jama.285.18.2370
[4]	Feinberg, W.M., Blackshear, J.L., Laupacis, A., et al. (1995) Prevalence age distribution and gender of patients with AF. Analysis and implacations. Archives of Internal Medicine, 155, 469-473. doi:10.1001/archinte.1995.00430050045005
[5]	Miyasaka, Y., Barnes, M.E., Gersh, B.J., et al. (2006) Secular trends in incidence of AF in Olmsted County Minnesoda. 1980-2000, and implications on the projections for future prevalence. Circulation, 114, 119-125. doi:10.1161/CIRCULATIONAHA.105.595140
[6]	Takshminarayan, K., Anderson, D.C., Qureshi, A.I., et al. (2008) Clinical epidemiology of AF and cerebrovascular events in the US. Neurologist, 14, 143-150. doi:10.1097/NRL.0b013e31815cffae
[7]	Furberg, C.D., Psaty, B.M., Manolio, T.A., et al. (1994) Prevalence of AF in elderly subjects (the Cardiovascular Health Study). American Journal of Cardiology, 74, 236-241. doi:10.1016/0002-9149(94)90363-8
[8]	Kannel, W.B., Wolf, P.A., Benjamin, E.L. and Levy, D. (1998) Prevalence, Incidence, prognosis, and predisposing conditions for AF: Population-based estimates. American Journal of Cardiology, 82, 2N-9N. doi:10.1016/S0002-9149(98)00583-9
[9]	Fuster, V., Rydén, L.E., David, S., Cannom, D.S., et al. (2006) ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation—Executive summary. Journal of the American College of Cardiology, 854-906. doi:10.1016/j.jacc.2006.07.009
[10]	Allessie, M., Ausma, J. and Schotten, U. (2002) Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research, 54, 230-246. doi:10.1016/S0008-6363(02)00258-4
[11]	Kumagai, K., Nakashima, H., Urata, H., et al. (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. Journal of the American College of Cardiology, 41, 2197- 2204. doi:10.1016/S0735-1097(03)00464-9
[12]	Dittrich, H.C., Erickson, J.S., Schneiderman, T., et al. (1989) Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. American Journal of Cardiology, 63, 193-197. doi:10.1016/0002-9149(89)90284-1
[13]	Wann, L.S., Curtis, A.B., January, C.T., et al. (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation, 123, 104-123. doi:10.1161/CIR.0b013e31820f14c0
[14]	Fuster, V., Lars, E., Rydén, L.E., Cannom, D.S., et al. (2007) Management of patients with atrial fibrillation. ACC/AHA pocket guideline. The ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation.
[15]	Gallagher, M.M., Guo, X.-H., Poloniecki, J.D., et al. (2001) Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. Journal of the American College of Cardiology, 38, 1498-1450. doi:10.1016/S0735-1097(01)01540-6
[16]	Mittal, S., Shcrvin, A., Stein, K.M., et al. (2000) Transthoracic cardioversion of atrial fibrillation: Comparison of rectilinear biphasic versus damped sine wave mono-phasic shocks. Circulation, 101, 1282-1287. doi:10.1161/01.CIR.101.11.1282
[17]	Stambler, B.S., Wood, M.A. and Ellenbogen, K.A. (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide repeat dose study investigators. Circulation, 94, 1613-1621. doi:10.1161/01.CIR.94.7.1613
[18]	Volgman, A.S., Carberry, P.A. and Stambler, B.S. (1998) Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. Journal of the American College of Cardiology, 31, 1414-1419. doi:10.1016/S0735-1097(98)00078-3
[19]	Oral, H., Souza, J.J. and Michaud, G.F. (1999) Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. The New England Journal of Medicine, 340, 1849-1854. doi:10.1056/NEJM199906173402401
[20]	Patel, C., Yan, G.X. and Kowey, P.R. (2009) Dronedarone. Circulation, 120, 636-644. doi:10.1161/CIRCULATIONAHA.109.858027
[21]	Piccini, J.P., Hasselblad, V., Peterson, E.D., et al. (2009) Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Journal of the American College of Cardiology, 54, 1089-1095. doi:10.1016/j.jacc.2009.04.085
[22]	Le Heuzey, J.Y., De Ferrari, G.M., Radzik, D., et al. (2010) A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. Journal of Cardiovascular Electrophysiology, 21, 597-605. doi:10.1111/j.1540-8167.2010.01764.x
[23]	Ellenbogen, K.A. (2011) Editor’s choice: FDA warns of severe liver injury association with dronedarone. Cardio Source News, Top News.
[24]	Atwood, J.E., Myers, J., Sandhu, S., et al. (1989) Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation. American Journal of Cardiology, 63, 45-48.
[25]	Tein, K.M., Borer, J.S., Hochreiter, C., et al. (1994) Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. American Journal of Cardiology, 74, 906-911. doi:10.1016/0002-9149(94)90584-3
[26]	Olshansky, B., Rosenfeld, L.E., Warner, A.L., et al. (2004) The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. Journal of the American College of Cardiology, 43, 1201-1208. doi:10.1016/j.jacc.2003.11.032
[27]	Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., et al. (2010) Lenient versus strict rate control in patients with atrial fibrillation. The New England Journal of Medicine, 362, 1363-1373. doi:10.1056/NEJMoa1001337
[28]	Cappato, R., Calkins, H., Chen, S.A., et al. (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation: Arrhythmia and Electrophysiology, 3, 32-38. doi:10.1161/CIRCEP.109.859116
[29]	Bertaglia, E., Tondo, C., De Simone, A., et al. (2010) Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: A 6-year multicentre experience. Europace, 12, 181-187. doi:10.1093/europace/eup349
[30]	Fogoros, R.N. (2011) Ablating atrial fibrillation. About.com Guide.
[31]	Karch, M.R., Zrenner, B., Deisenhofer, I., et al. (2005) Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: A randomized comparison between 2 current ablation strategies. Circulation, 111, 2875-2880. doi:10.1161/CIRCULATIONAHA.104.491530
[32]	Hindricks, G., Piorkowski, C., Tanner, H., et al. (2005) Perception of atrial fibrillation before and after radiofrequency catheter ablation: Relevance of asymptomatic arrhythmia recurrence. Circulation, 112, 307-313. doi:10.1161/CIRCULATIONAHA.104.518837
[33]	Ozcan, C., Jahangir, A. and Friedman, P.A. (2001) Long-Term Survival after Ablation of the Atrioventricular Node and Implantation of a Permanent Pacemaker in Patients with atrial fibrillation. The New England Journal of Medicine, 344, 1043-1051. doi:10.1056/NEJM200104053441403
[34]	Kay, G.N., Ellenbogen, K.A., Giudici, M., et al. (1998) The ablate and pace trial: a prospective study of catheter ablation of the AV conduction system and permanent pa-cemaker implantation for treatment of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2, 121-135. doi:10.1023/A:1009795330454
[35]	Tai, C.T., Tsai, C.F., Hsieh, M.H., et al. (2001) Effects of Cavotricuspid isthmus ablation on atrioventricular node electrophysiology in patients with typical atrial flutter Circulation, 104, 1501-1505. doi:10.1161/hc3801.078813
[36]	Hoffmann, B.A., Koops, A. and Rostock, T. (2010) Interactive real-time mapping and catheter ablation of the cavotricuspid isthmus guided by magnetic resonance imaging in a porcine model. European Heart Journal, 31, 450- 456. doi:10.1093/eurheartj/ehp460
[37]	The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1996) The effect of low-dose warfarin on the risk of stroke in patients Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low- intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrilation III randomised clinical trial. Lancet, 348, 633- 638. doi:10.1016/S0140-6736(96)03487-3
[38]	Posada, I.S. and Barriales, V. (1999) Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. American Heart Journal, 138, 137-143. doi:10.1016/S0002-8703(99)70259-0
[39]	Stroke Prevention in Atrial Fibrillation Investigators (1994) Warfarin versus aspirin for prevention of throm-boembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet, 343, 687-691.
[40]	Hellemons, B.S., Langenberg, M., Lodder, J., et al. (1999) Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin. British Medical Journal, 319, 958-964. doi:10.1136/bmj.319.7215.958
[41]	Hart, R.G., Benavente, O., McBride, R. and Pearce, L.A. (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Annals of Internal Medicine, 131, 492-501.
[42]	Connolly, S., Pogue, J., Hart, R., et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Ibesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial with Ibesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet, 367, 1903-1912. doi:10.1016/S0140-6736(06)68845-4
[43]	Connolly, S.J., Pogue, J., Hart, R.G., et al. (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England Journal of Medicine, 360, 2066-2078. doi:10.1056/NEJMoa0901301
[44]	Holmes, D.R. Jr., Kereiakes, D.J., et al. (2009) Combining antiplatelet and anticoagulant therapies. Journal of the American College of Cardiology, 54, 95-109. doi:10.1016/j.jacc.2009.03.044
[45]	Holmes, D.R., Reddy, V.Y., Turi, Z.G., et al. (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet, 374, 534-542. doi:10.1016/S0140-6736(09)61343-X
[46]	Gulcher, J. (2008) From bad to worse. The conference connection. Highlights of the AHA Scientific Sessions, New Orleans, 1, 4-5.
[47]	Hart, R.G., Halperin, J.L., Peace, L.A., et al. (2003) Lessons from the stroke prevention in AF trials. Annals of Internal Medicine, 138, 831-838.
[48]	Levine, M.N., Raskob, G., Landefeld, S., et al. (2001) Hemorrhygic complication of anticoagulant treatment Chest, 119, 108s-121s. doi:10.1378/chest.119.1_suppl.108S
[49]	Waldo, A.L., Becker, R.C., Tapson, V.F., et al. (2005) Hospitalized patients with AF and high risk of stroke are not being provided with adequate anticoagulation agents. Journal of the American College of Cardiology, 46, 1729- 1736. doi:10.1016/j.jacc.2005.06.077
[50]	ARISTOTLE trial (2011) New oral anticoagulant apixaban versus warfarin in atrial fibrillation. The New England Journal of Medicine, 365, 765-775.
[51]	Patel, M.R., Mahaffey, K.W., Garg, J., et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365, 883- 891. doi:10.1056/NEJMoa1009638
[52]	Madden, J. (1948) Resection of left atrial appendix. Journal of the American Medical Association, 140, 769- 772. doi:10.1001/jama.1949.02900440011003
[53]	Cox, J.L., et al. (1991) Maze operation in patients with atrial fibrillation. Journal of Thoracic and Cardiovascular Surgery, 101, 406-426.
[54]	Lawric, G.M. (2008) Surgery for atrial fibrillation. JMDHVC, 4, 8-11.